Travis Murdoch, HI-Bio CEO
November 1, 2022 06:14 AM EDTUpdated 12:40 PM
Financing
Startups

That se­cre­tive ARCH biotech with two an­ti­bod­ies from Mor­phoSys? It’s now got $120M

Lei Lei Wu

News Reporter

In June, HI-Bio, short for Hu­man Im­munol­o­gy Bio­sciences, li­censed two can­di­dates from Ger­man biotech Mor­phoSys — felzartam­ab for two au­toan­ti­body kid­ney dis­eases, and HIB210, which goes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times